Phase 2 N=64 Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
Cystic Fibrosis
Primary: Percentage Flow-Mediated Dilation (FMD) — 5.64; 5.32; 6.29; 7.21 percentage of change in FMD
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=238 Study of Ataluren (PTC124™) in Cystic Fibrosis
Cystic Fibrosis
Primary: Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline — 62.092; 60.232 percentage of predicted FEV1 — p=0.3264
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
N/A N=79 Cystic Fibrosis Related Bone Disease: the Role of CFTR
Cystic Fibrosis Related Bone Disease
Primary: Bone Microarchitecture and Strength Measures of the Radius and Tibia — 44.6; 40.1; 43.7 mgHA/cm3 — p=0.77
N/A N=59 Nasal Epithelial Cells/Blood Lymphocyte Markers for Cystic Fibrosis (CF)/CF Pulmonary Exacerbations
Cystic Fibrosis
Primary: The Number of Participants With Blood and Sputum Samples Collected — 18; 27; 0; 14 Participants
Phase 2 N=8 Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
Cystic Fibrosis
Primary: Part A: Change From Baseline in Total Ventilation Defect Defined by Hyperpolarized Helium 3 Magnetic Resonance Imaging (3He-MRI) at Day 43 — -8.20 percentage of total…
Phase 3 N=191 Extension Study of Ataluren (PTC124) in Cystic Fibrosis
Cystic Fibrosis
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 100; 97.9; 14.7; 18.8 percent of participants
N/A N=267 Early Intervention in Cystic Fibrosis Exacerbation
Cystic Fibrosis
Primary: Change in FEV1 — -0.07; -0.08 Liters
N/A N=21 Absorptive Clearance in the Cystic Fibrosis Airway
Cystic Fibrosis
Primary: Absorptive Clearance Rate — 42; 32 percentage of DTPA absoprtion per hour
Phase 3 N=282 Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 90; 180 participants
N/A N=38 Using Rheological Methods to Characterize Cystic Fibrosis (CF) Sputum and the Effects of Mucoactive Agents
Cystic Fibrosis
Primary: Shear Rheology — 6.0; 1.8 Pascal
Phase 2 N=151 Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
Cystic Fibrosis (CF)
Primary: Change in P. Aeruginosa Density — 0.23; -0.31; -0.31; -0.73 log10 CFU/g sputum — p=0.0014
N/A N=10 Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
Cystic Fibrosis · Lung Transplant
Primary: Steady-state Pharmacokinetics of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Stable Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Recipients…
N/A N=402 Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants
N/A N=10 Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Sweat Chloride Concentration — NA mmol/L
Phase 2 N=36 Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease
Cystic Fibrosis
Primary: Change in Sputum Elastase Activity — -57 micrograms/mL
Phase 3 N=330 MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Time to an Exacerbation — 58; 51.5 Days — p=0.0715
Phase 1 N=20 Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
Cystic Fibrosis
Primary: Absorptive Clearance Rate After Isotonic Saline Inhalation — 32.0 percent cleared / 80 minutes
Phase 2 N=304 Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Cystic Fibrosis · Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization — 24; 26; 29; 21 number of participants — p=0.86
N/A N=21 FDG-PET Imaging in Young Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Kinetic Influx Constant (Ki) — 0.009; 0.013 mL/min/mL
Phase 3 N=41 A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Primary: Coefficient of Fat Absorption (CFA) — 88.1; 89.5 percentage of fat intake
Phase 2 N=8 CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)
Cystic Fibrosis
Primary: Change in Sputum Bacterial Culture — -0.59; -0.89 CFU/mL
Phase 2 N=200 EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients
Cystic Fibrosis
Primary: Difference From Placebo in Absolute Change From Baseline in Forced Expiratory Volume in 1 Second Percent Predicted (ppFEV1) — -1.30; -3.76; -2.53; -2.69 FEV1 percent…
N/A N=130 Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
Phase 1 N=18 Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation
Cystic Fibrosis
Primary: Intra-subject Change From Baseline of CFTR-mediated Total Chloride Transport as Measured by Nasal Potential Difference (NPD). — 1.86; -0.75; -1.11; 1.66 mV
Phase 2 N=19 Effects of Sildenafil on CFTR-dependent Ion Transport Activity
Cystic Fibrosis
Primary: Change in Sodium Conductance by Nasal Potential Difference (NPD) — -0.70; 1.81 mV
Phase 2 N=85 Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events. — 14; 13; 15; 21 Participants
Phase 2 N=30 A Study of Ataluren in Pediatric Participants With Cystic Fibrosis
Cystic Fibrosis
Primary: Change From Baseline in Total Chloride Transport at Day 14 of Cycles 1 and 2 — 1.45; 0.66; -2.81; -2.69 millivolts (mV) — p=0.133
Phase 2 N=93 Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
Cystic Fibrosis
Primary: Safety and Tolerability Based on Adverse Events (AEs) — 17; 16; 15; 16 participants
Phase 1 N=10 Clearance of 25-hydroxyvitamin D in Cystic Fibrosis
Cystic Fibrosis
Primary: Metabolic Clearance of D6-25(OH)D3 — 397; 342 mL/day